2021
Inactive status is an independent predictor of liver transplant waitlist mortality and is associated with a transplant centers median meld at transplant
Merola J, Gan G, Stewart D, Noreen S, Mulligan D, Batra R, Haakinson D, Deng Y, Kulkarni S. Inactive status is an independent predictor of liver transplant waitlist mortality and is associated with a transplant centers median meld at transplant. PLOS ONE 2021, 16: e0260000. PMID: 34793524, PMCID: PMC8601542, DOI: 10.1371/journal.pone.0260000.Peer-Reviewed Original ResearchMeSH KeywordsEligibility DeterminationForecastingHumansLiverLiver TransplantationModels, TheoreticalPrognosisTissue DonorsTransplantsWaiting ListsConceptsDonor service areasWaitlist mortalityTransplant centersMedian MELDHigh mortalityStatus changesLiver transplant waitlist mortalityDeceased donor transplantsInactive statusTransplant probabilityInactive patientsMELD scoreDonor transplantsHazard ratioIndependent predictorsTransplant ratesCare coordinationMortalityPatientsTransplantLevel cohortsTertileSignificant differencesCohortMELD
2014
Written informed consent for living liver donor evaluation: Compliance with centers for medicare and medicaid services and organ procurement and transplantation network guidelines and alibi offers
Thiessen C, Kim YA, Yoo PS, Rodriguez‐Davalos M, Mulligan D, Kulkarni S. Written informed consent for living liver donor evaluation: Compliance with centers for medicare and medicaid services and organ procurement and transplantation network guidelines and alibi offers. Liver Transplantation 2014, 20: 416-424. PMID: 24415564, DOI: 10.1002/lt.23822.Peer-Reviewed Original ResearchSegmental Grafts in Adult and Pediatric Liver Transplantation: Improving Outcomes by Minimizing Vascular Complications
Rodriguez-Davalos MI, Arvelakis A, Umman V, Tanjavur V, Yoo PS, Kulkarni S, Luczycki SM, Schilsky M, Emre S. Segmental Grafts in Adult and Pediatric Liver Transplantation: Improving Outcomes by Minimizing Vascular Complications. JAMA Surgery 2014, 149: 63-70. PMID: 24284803, DOI: 10.1001/jamasurg.2013.3384.Peer-Reviewed Original ResearchConceptsDonor liver transplantSegmental graftsRight lobeLiver transplantVascular complicationsSegmental allograftsDeceased donorsLateral segmentConsecutive liver transplant patientsDonor graft recipientsHepatic artery stenosisReduced-size graftsWaiting list mortalityLiver transplant patientsPortal vein thrombosisPediatric liver transplantationMultidisciplinary team approachInnovative surgical techniquesBiliary complicationsSegmental transplantsStrict patientGraft survivalList mortalityLiver transplantationTransplant patients
2011
Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation
Cimsit B, Assis D, Caldwell C, Arvelakis A, Taddei T, Kulkarni S, Schilsky M, Emre S. Successful Treatment of Fibrosing Cholestatic Hepatitis After Liver Transplantation. Transplantation Proceedings 2011, 43: 905-908. PMID: 21486625, DOI: 10.1016/j.transproceed.2011.02.034.Peer-Reviewed Case Reports and Technical NotesConceptsLiver allograft rejectionHepatitis C virusRenal graft rejectionAllograft rejectionHCV recurrenceCholestatic hepatitisGraft rejectionHCV RNAPatient survivalEnd-stage liver disease (MELD) scoreOne-year patient survivalIFN/RBV therapyFIBROSING CHOLESTATIC HEPATITISHistologic HCV recurrenceIFN/ribavirinOne-year graftSuccessful salvage strategiesTime of OLTHCV RNA levelsLiver Disease scoreAnti-HCV therapyCohort of patientsEarly graft failureFCH groupOLT recipientsPediatric Liver Transplantation for Inherited Metabolic Liver Disease: A Single-Center Experience
Rosencrantz R, Cimsit B, Seashore M, Arvelakis A, Kulkarni S, Ghiroli M, Emre S. Pediatric Liver Transplantation for Inherited Metabolic Liver Disease: A Single-Center Experience. Transplantation Proceedings 2011, 43: 896-900. PMID: 21486623, DOI: 10.1016/j.transproceed.2011.02.035.Peer-Reviewed Original ResearchConceptsMetabolic liver diseaseLiver diseaseMS patientsMetabolic diseasesLiver transplantLiver transplantationStatus 1Pediatric liver transplant recipientsPELD/MELD scoreM groupHeterozygote parentsNeurologic motor functionAcute cellular rejectionDonor liver transplantLiver transplant recipientsDetectable EBV DNAPediatric liver transplantationSingle-center experiencePatients' overall survivalPatient survival outcomesMajority of childrenGenetic liver diseasesCellular rejectionCMV viremiaExcellent allograftCombined Liver Kidney Transplantation: Critical Analysis of a Single-Center Experience
Cimsit B, Schilsky M, Moini M, Cartiera K, Arvelakis A, Kulkarni S, Formica R, Caldwell C, Taddei T, Asch W, Emre S. Combined Liver Kidney Transplantation: Critical Analysis of a Single-Center Experience. Transplantation Proceedings 2011, 43: 901-904. PMID: 21486624, DOI: 10.1016/j.transproceed.2011.02.033.Peer-Reviewed Original ResearchConceptsLiver-kidney transplantationHigh MELD scoreKidney transplantationMELD scoreKidney diseaseEnd-stage liver disease (MELD) scoreCombined liver-kidney transplantationGraft/patient survivalLow glomerular filtration rateOrgan allocation algorithmsPrimary biliary sclerosisRecurrence of HCVSevere HCV recurrenceTransplantation of patientsLiver Disease scoreSerum creatinine levelsRenal allograft rejectionSingle-center experienceGlomerular filtration rateHepatitis C virusPolycystic kidney diseaseBiliary sclerosisHCV recurrenceIschemic hepatitisOLT patients
2010
Use of model for end‐stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature
Caldwell C, Werdiger N, Jakab S, Schilsky M, Arvelakis A, Kulkarni S, Emre S. Use of model for end‐stage liver disease exception points for early liver transplantation and successful reversal of hepatic myelopathy with a review of the literature. Liver Transplantation 2010, 16: 818-826. PMID: 20583082, DOI: 10.1002/lt.22077.Peer-Reviewed Original ResearchConceptsEarly liver transplantationHepatic myelopathyLiver transplantationSpastic paraparesisEnd-Stage Liver Disease (MELD) exception pointsEnd-Stage Liver Disease exceptionCases of LTException pointsCorticospinal tract functionFurther hepatic decompensationSetting of cirrhosisSignificant neurological improvementProgressive spastic paraparesisMELD exception pointsHepatic decompensationMELD scoreNeurological improvementFull ambulationNeurological benefitsPortosystemic shuntingHM patientsClinical stageUnited NetworkWheelchair dependencyEarly transplantation
2006
Ethics in Liver Transplantation
Kulkarni S, Cronin D. Ethics in Liver Transplantation. Seminars In Liver Disease 2006, 26: 234-238. PMID: 16850372, DOI: 10.1055/s-2006-947299.Peer-Reviewed Original ResearchMeSH KeywordsHealth Care RationingHumansLiver TransplantationPatient SelectionSeverity of Illness IndexTissue DonorsConceptsEnd-stage liver diseaseDeceased donor liversLiver transplantationLiver diseaseManagement of comorbiditiesDeceased donor kidneysGraft survivalPreferred therapyLifesaving therapyCurrent allocation systemSurgical techniqueTransplantationPatientsLiverTherapyDiseaseInadequate supplyDeficiencyComorbiditiesImmunosuppressionMELDKidneyMortalitySuch deficienciesSpectacular improvementLiving donor liver transplantation for pediatric and adult recipients
Kulkarni S, Malagò M, Cronin DC. Living donor liver transplantation for pediatric and adult recipients. Nature Reviews Gastroenterology & Hepatology 2006, 3: 149-157. PMID: 16511549, DOI: 10.1038/ncpgasthep0437.Peer-Reviewed Original ResearchEthical tensions in solid organ transplantation: the price of success.
Kulkarni S, Cronin DC. Ethical tensions in solid organ transplantation: the price of success. World Journal Of Gastroenterology 2006, 12: 3259-64. PMID: 16718849, PMCID: PMC4087972, DOI: 10.3748/wjg.v12.i20.3259.Peer-Reviewed Original Research
2003
The sickest first? Disparities with model for end‐stage liver disease‐based organ allocation: One region's experience
Schaffer RL, Kulkarni S, Harper A, Millis JM, Cronin DC. The sickest first? Disparities with model for end‐stage liver disease‐based organ allocation: One region's experience. Liver Transplantation 2003, 9: 1211-1215. PMID: 14586883, DOI: 10.1053/jlts.2003.50192.Peer-Reviewed Original ResearchConceptsCadaver liversMELD scoreHepatocellular carcinomaOrgan allocationRegion patientsEnd-stage liver diseaseEquitable organ distributionMean MELD scoreMedian MELD scoreHigh MELD scoreLiver transplant programNumber of transplantationsOrgan Sharing regionsLiver recipientsPretransplantation mortalityMELD exceptionsLiver diseaseSingle centerUnited NetworkTransplant programsWaiting listTransplantationEvidence-based systemOrgan procurementTransplantation NetworkSolid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis
Kulkarni S, Naureckas E, Cronin DC. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis. Transplantation 2003, 75: 899-901. PMID: 12660522, DOI: 10.1097/01.tp.0000054842.34916.e8.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsSolid organ transplantsSevere sepsisDrotrecogin alfaTransplant recipientsMultisystem organ failureImmunosuppressed recipientsOrgan failurePatient populationEffective adjuvantProcoagulant responseSepsisHigh mortalityAlfaRecipientsTransplantConventional managementTreatmentInitial successAdjuvantMortality